NCT05627856View on ClinicalTrials.gov

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
NK/T Cell LymphomaVascular Immunomother T Cell LymphomaNon-Hodgkin Lymphoma
Interventions
DRUG

GNC-038

Administration by intravenous infusion

Trial Locations (2)

510050

Sun Yat-sen University Cancer Center, Guangzhou

510120

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY